Bamlanivimab
Modify Date: 2024-01-10 22:45:42
Bamlanivimab structure
|
Common Name | Bamlanivimab | ||
|---|---|---|---|---|
| CAS Number | 2423943-37-5 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of BamlanivimabBamlanivimab (Anti-Human SARS-CoV-2) is the first COVID-19 monoclonal antibody (mAb) to be granted Emergency Use Authorization (EUA) in November 2020 by the U.S. Food and Drug Administration (FDA). However, Bamlanivimab is withdrawn in April 2021 following the rise of SARS-CoV-2 virus variants resistant to Bamlanivimab[1]. |
| Name | Bamlanivimab |
|---|
| Description | Bamlanivimab (Anti-Human SARS-CoV-2) is the first COVID-19 monoclonal antibody (mAb) to be granted Emergency Use Authorization (EUA) in November 2020 by the U.S. Food and Drug Administration (FDA). However, Bamlanivimab is withdrawn in April 2021 following the rise of SARS-CoV-2 virus variants resistant to Bamlanivimab[1]. |
|---|---|
| Related Catalog | |
| Target |
SARS-CoV-2[1] |
| References |
| No Any Chemical & Physical Properties |